CN117281846B - Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof - Google Patents

Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof Download PDF

Info

Publication number
CN117281846B
CN117281846B CN202311054722.0A CN202311054722A CN117281846B CN 117281846 B CN117281846 B CN 117281846B CN 202311054722 A CN202311054722 A CN 202311054722A CN 117281846 B CN117281846 B CN 117281846B
Authority
CN
China
Prior art keywords
chinese medicine
traditional chinese
fine powder
preparation
ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202311054722.0A
Other languages
Chinese (zh)
Other versions
CN117281846A (en
Inventor
樊新荣
石晓路
樊湘
冯淑怡
孙丽华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXPERIMENTAL RESEARCH CENTER CHINA ACADEMY OF CHINESE MEDICAL SCIENCES
Original Assignee
EXPERIMENTAL RESEARCH CENTER CHINA ACADEMY OF CHINESE MEDICAL SCIENCES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EXPERIMENTAL RESEARCH CENTER CHINA ACADEMY OF CHINESE MEDICAL SCIENCES filed Critical EXPERIMENTAL RESEARCH CENTER CHINA ACADEMY OF CHINESE MEDICAL SCIENCES
Priority to CN202311054722.0A priority Critical patent/CN117281846B/en
Publication of CN117281846A publication Critical patent/CN117281846A/en
Application granted granted Critical
Publication of CN117281846B publication Critical patent/CN117281846B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese medicine composition for improving hypoxia tolerance, a preparation method and application thereof. The traditional Chinese medicine composition provided by the invention is composed of four medicines of American ginseng, pseudo-ginseng, ganoderma lucidum and donkey-hide gelatin. The traditional Chinese medicine composition has the functions of resisting oxidation, relieving fatigue and enhancing immunity, and has good effect of improving the symptoms of dizziness, headache, palpitation, shortness of breath and the like caused by deficiency of qi and blood stasis.

Description

Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving hypoxia tolerance, a preparation method and application thereof.
Background
Hypoxia refers to a pathological process in which the metabolic, functional and morphological structure of a tissue is abnormally altered due to insufficient oxygen supply or oxygen usage of the tissue. When the oxygen supply to the body is less than oxygen demand, the cells will adjust their metabolic levels to accommodate the tissue needs, a process that affects the life processes of cell survival, proliferation, exercise, metabolism, pH regulation, extracellular matrix function, inflammatory cell recruitment, and angiogenesis.
The effect of hypoxia on the body depends on the extent, rate, duration and functional metabolic state of the body at which hypoxia occurs. Hypoxia, which is generally less severe, mainly causes compensatory reactions in the body, such as changes in blood circulation, enhanced respiration, and acceleration of erythropoiesis. When some animals suffer from severe hypoxia, the animals suffer from serious metabolic dysfunction and even local cell, tissue and organ necrosis, especially the hypoxia of vital organs such as brain and heart, often directly causes death of the animals. Hypoxia thus plays a central role in the pathogenesis and pathophysiology of cardiovascular disease, neurological disease, respiratory disease, etc.
In addition, the plateau anoxic environment can cause injury to important organs such as brain, lung, heart, stomach and intestine in human bodies, wherein brain tissues with vigorous metabolism, large blood flow and large oxygen consumption have very poor tolerance to hypoxia, and are extremely vulnerable to hypoxia injury. The acute mountain sickness, the altitude headache, the altitude cerebral edema and other cerebral injury manifestations occur when the organism rapidly enters the anoxic environment.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for improving the hypoxia tolerance, which has the functions of resisting oxidation, relieving fatigue and enhancing immunity, and has good effects of improving hypoxia diseases such as dizziness, headache, palpitation, shortness of breath and the like caused by deficiency of qi and blood stasis.
In order to achieve the above purpose, the present invention provides the following technical solutions:
in a first aspect, the invention provides a traditional Chinese medicine composition, which comprises the following components in parts by weight: 2-8 parts of American ginseng, 3-12 parts of pseudo-ginseng, 4-16 parts of lucid ganoderma and 3-12 parts of donkey-hide gelatin.
Preferably 2-4 parts of American ginseng, 6-12 parts of pseudo-ginseng, 4-8 parts of lucid ganoderma and 6-12 parts of donkey-hide gelatin; more preferably 2 parts of American ginseng, 6 parts of pseudo-ginseng, 4 parts of lucid ganoderma and 12 parts of donkey-hide gelatin.
In a second aspect, the present invention further provides a preparation method of the traditional Chinese medicine composition, comprising the following steps:
s1, respectively pulverizing the American ginseng, the pseudo-ginseng and the donkey-hide gelatin, and sieving to obtain American ginseng fine powder, pseudo-ginseng fine powder and donkey-hide gelatin fine powder;
s2, sieving, drying and breaking walls of the ganoderma lucidum spore powder to obtain ganoderma lucidum fine powder;
S3, mixing the American ginseng fine powder, the pseudo-ginseng fine powder, the donkey-hide gelatin fine powder and the lucid ganoderma fine powder according to a proportion.
In step S1, the mesh number of the sieve is 80-150 mesh, preferably 80 mesh.
In the step S2, the wall breaking rate of the ganoderma lucidum fine powder is more than or equal to 95%, and the fineness is more than 300 meshes.
The wall breaking is realized by low-temperature physical differential rolling; the low-temperature physical differential rolling is carried out according to the following operation: sieving the spore powder of the ganoderma lucidum, drying at a low temperature in vacuum, and then embrittling and breaking walls of cell walls at a low temperature; wherein the embrittlement temperature is-20 ℃.
In a third aspect, the present invention further provides a Chinese medicinal preparation comprising the Chinese medicinal composition.
The traditional Chinese medicine preparation is in the form of suspension, capsule, powder, pill, tablet, granule or paste.
In the traditional Chinese medicine suspension, the concentration of the traditional Chinese medicine composition is 0.1-0.3g/ml, preferably 0.136g/ml.
In a fourth aspect, the invention further provides application of the traditional Chinese medicine composition or the traditional Chinese medicine preparation in preparing products with the functions of resisting anoxia, resisting fatigue and enhancing immunity. Preferably, the product is a health food or a pharmaceutical product.
The anti-hypoxia medicament is a medicament for resisting hypoxia symptoms such as dizziness, headache, palpitation, shortness of breath and the like which occur due to deficiency of qi and blood stasis.
In a fifth aspect, the present invention further provides an application of the traditional Chinese medicine composition or the traditional Chinese medicine preparation in preparing a product for treating dysfunction or disease caused by acute hypoxia.
Such as altitude hypoxia, etc.
The diseases are cardiovascular diseases, nervous system diseases, respiratory diseases, etc. caused by anoxia, such as acute altitude sickness, altitude headache, altitude cerebral edema, etc.
In the application, the administration dosage of the traditional Chinese medicine composition or the traditional Chinese medicine preparation is as follows:
The effective administration dose of the animal is as follows: 0.01-0.03g is administered per 10g body weight per day;
according to equivalent dose conversion and the crude drug amount, the effective administration dose of the human body is as follows: the dosage is 0.11g-0.33g per kg body weight per day.
The beneficial effects obtained by the invention are as follows:
The prescription consists of four medicines of American ginseng, pseudo-ginseng, ganoderma lucidum and donkey-hide gelatin. The composition has antioxidant, fatigue relieving and immunity enhancing effects.
Fang Zhongxi radix Panacis Quinquefolii is used as the principal drug, has effects of benefiting lung yin, clearing deficient fire, promoting salivation, quenching thirst, and is mainly used for treating chronic cough due to lung deficiency, blood loss, dry throat, thirst, dysphoria due to deficiency heat, and radix Panacis Quinquefolii recorded in "Ben Cao Renew"): for treating excessive lung fire, cough with excessive phlegm, qi deficiency, asthma, blood loss, fatigue, essence securing and tranquillization, and other deficiency symptoms. The ministerial drugs ganoderma lucidum are used for heart, lung, spleen and kidney channels, have the effects of tonifying qi and soothing nerves, relieving cough and asthma, and are mainly used for treating restlessness of heart spirit, insomnia and palpitation, cough and asthma with excessive phlegm, consumptive disease and the like. The monarch drug and the American ginseng are matched with the ministerial drug, namely the ganoderma lucidum, and have the effects of tonifying lung and spleen, tranquilizing and improving intelligence. Donkey-hide gelatin enters lung, liver and kidney meridians, has the functions of enriching blood and stopping bleeding, nourishing yin and moisturizing lung, is matched with monarch drug American ginseng, and can tonify qi and blood, and treat both lung and spleen. Notoginseng radix has effects of dispersing blood stasis, stopping bleeding, detumescence, relieving pain, promoting blood circulation, and can prevent colla Corii Asini from greasy, and nourishing blood, and prevent Notoginseng radix from promoting blood circulation. The four medicines are combined, mainly tonifying and eliminating, and have the effects of tonifying qi, activating blood, nourishing blood and tranquillizing. Has good effect of improving dizziness, headache, palpitation, short breath and other anoxia symptoms caused by deficiency of qi and blood stasis.
Drawings
FIG. 1 is a graph showing the normal pressure hypoxia survival rate in the effect verification experiment 1.
FIG. 2 shows the normal pressure hypoxia tolerance survival time in effect verification experiment 1.
FIG. 3 is a graph showing the survival rate of the swim under load in the effect verification experiment 1.
Fig. 4 shows the survival time of the swim under load in the effect verification experiment 1.
FIG. 5 shows organ indexes after load swimming in effect verification experiment 1; wherein (a) is thymus index and (b) is spleen index.
Fig. 6 is a nitrous poisoning survival curve in effect verification experiment 1.
Fig. 7 shows the nitrous poisoning survival time in the effect verification experiment 1.
FIG. 8 shows the effect of different sample formulations on the normal pressure hypoxia survival rate in effect verification experiment 2; wherein (a) represents American ginseng group, (b) represents pseudo-ginseng group, (c) represents ganoderma lucidum group, (d) represents donkey-hide gelatin group, (e) represents formula 1, (f) represents formula 2, (g) represents formula 3, (h) represents formula 4, (i) represents formula 5, and (j) represents formula 6.
Fig. 9 is a graph showing the effect of different sample formulations on the survival time of hypoxia at normal pressure in experiment 2.
Detailed Description
The invention will be further illustrated with reference to the following specific examples, but the invention is not limited to the following examples.
The experimental methods used in the following examples are conventional methods unless otherwise specified.
Reagents, materials, instruments and the like used in the examples described below are commercially available unless otherwise specified.
Example 1
The preparation method comprises the following steps:
(1) Pulverizing radix Panacis Quinquefolii, notoginseng radix and colla Corii Asini mechanically, and sieving with 80 mesh sieve to obtain radix Panacis Quinquefolii fine powder, notoginseng radix fine powder and colla Corii Asini fine powder.
(2) Sieving Ganoderma spore powder, vacuum drying at low temperature, and physically grinding at-20deg.C to break wall to obtain Ganoderma fine powder with wall breaking rate of 95% or more and fineness of 300 mesh or more.
(3) The powder is prepared from American ginseng, pseudo-ginseng, ganoderma lucidum and donkey-hide gelatin according to the mass ratio of 8:12:16:12, preparing a suspension with the concentration of 0.273g/ml after uniformly mixing, and carrying out ultrasonic vibration for 1h at 55-60 ℃.
Effect verification experiment 1
1. Experimental animals and groups
80 ICR mice were fed adaptively for 1 week and had a weight of about 25g-30g. The weight was randomly divided into 2 groups of 40, i.e. control, formula (example 1). After animals were grouped, the control group was filled with pure water (0.1 mL/10 g), the formula was filled with the formula drug suspension (0.1 mL/10 g), and the stomach was continuously filled for 1 week. The following pharmacodynamic verification was performed according to the above grouping method.
2. Atmospheric hypoxia tolerance experiment
Taking 18 mice in a control group and a formula group respectively, after the last administration for 1h, putting the mice into 250mL grinding bottles (1 each bottle) containing 10g of sodium lime respectively, sealing the bottle mouth, recording the survival time of the mice, and comparing the groups.
3. Mouse load swimming experiment
Taking 12 mice in a control group and a formula group, respectively weighing the mice after the last administration for 1h, putting the mice with tail root parts loaded with 5% weight lead strips into a swimming box (water temperature 25+/-1 ℃ and water depth of about 25 cm) for swimming, and recording the time from the start of the swimming of the mice to the death. Immediately after the death of the mice, the mice are fished out and wiped dry, thymus and spleen are taken by dissection, fat and connective tissue around viscera are removed, blood is adsorbed by filter paper, the accurate weighing is carried out, and immune organ indexes are calculated according to the following formula: immune organ index = organ mass (g)/mouse mass (g) ×100%.
4. Nitrous acid poisoning survival experiment
10 Mice in the control group and the formula group are taken, the mice in each group are respectively weighed after the last administration for 1 hour, the animals in each group are injected with sodium nitrite in the abdominal cavity according to the dosage of 200mg/kg (the injection amount is 0.1mL/10 g), and the survival time of the animals is immediately recorded in a timing way.
5. Analysis method
Compared to the control group, the survival time was tested by t-test and the survival curve by Log-rank (Mantel-Cox).
6. Results
6.1 Atmospheric pressure hypoxia tolerance experiment
As shown in fig. 1 and fig. 2, compared with the control group, the formula group shows an extended survival time, including an increase in minimum survival time and maximum survival time, and the survival rate curve (P < 0.05) and the average survival time (P < 0.05) are significantly different, so that the pharmaceutical composition provided by the invention has the capability of improving normal pressure hypoxia tolerance.
6.2 Mouse load swimming experiment
As shown in fig. 3 and 4, the survival rate curve (P < 0.05) and the mean survival time (P < 0.05) of the formula group were significantly different from the control group. As shown in FIG. 5, compared with the control group, the thymus index of the formula group is increased (P < 0.05), and the spleen index is not different (P > 0.05), so that the pharmaceutical composition provided by the invention has the anti-fatigue capability and the immunity enhancing function.
6.3 Nitrous acid poisoning survival experiments
As shown in fig. 6 and fig. 7, compared with the control group, the survival rate curves (P < 0.05) of the formula groups have significant differences, including increasing the minimum survival time and the maximum survival time, and the average survival time (P < 0.05) has significant differences, thereby indicating that the pharmaceutical composition provided by the invention has the capability of improving hypoxia tolerance.
Example 2
The formula comprises the following components: the traditional Chinese medicine comprises the following components in parts by weight: 2:3:8:6. Namely, formulation 3.
Prepared according to the procedure described in example 1.
Example 3
The formula comprises the following components: the traditional Chinese medicine comprises the following components in parts by weight: 2:6:4:12. Namely formulation 4.
Prepared according to the procedure described in example 1.
Example 4
The formula comprises the following components: the traditional Chinese medicine comprises the following components in parts by weight: 4:12:16:3. Namely formulation 5.
Prepared according to the procedure described in example 1.
Example 5
The formula comprises the following components: the traditional Chinese medicine comprises the following components in parts by weight: 8:12:8:6. Namely formulation 6.
Prepared according to the procedure described in example 1.
Effect verification experiment 2
1. Experimental animals and groups
ICR mice 132, after 1 week of adaptive feeding, had a body weight of about 25g-30g. The groups were randomly 11 according to body weight, 12 in each group, and the group and mode of administration were as follows.
After animals were grouped, control group 1 was filled with pure water (0.1 mL/10 g), and the formula was filled with the formula drug suspension (0.1 mL/10 g) and stomach was continuously filled for 1 week. The following pharmacodynamic verification was performed according to the above grouping method.
Table 1 modes of administration for each group
Group of Formula (mass ratio) Concentration of
Control group Pure water -
American ginseng group American ginseng 0.045g/ml
Notoginseng group Pseudo-ginseng 0.068g/ml
Ganoderma lucidum group Ganoderma lucidum 0.091g/ml
Donkey-hide gelatin group Donkey-hide gelatin 0.068g/ml
Formula 1 American ginseng, notoginseng: 8:12 0.114g/ml
Formula 2 (example 1) American ginseng, notoginseng, ganoderma lucidum, donkey-hide gelatin: 8:12:16:12 0.273g/ml
Formulation 3 (example 2) American ginseng, notoginseng, ganoderma lucidum, donkey-hide gelatin: 2:3:8:6 0.108g/ml
Formula 4 (example 3) American ginseng, notoginseng, ganoderma lucidum, donkey-hide gelatin: 2:6:4:12 0.136g/ml
Formulation 5 (example 4) American ginseng, notoginseng, ganoderma lucidum, donkey-hide gelatin: 4:12:16:3 0.199g/ml
Formulation 6 (example 5) American ginseng, notoginseng, ganoderma lucidum, donkey-hide gelatin: 8:12:8:6 0.193g/ml
2. Atmospheric hypoxia tolerance experiment
Compared with the effect verification experiment 1, the experimental method is different in that: in order to verify the difference of the functions of different components or formulas, the volume of the grinding bottle in the experiment is changed to 500mL, the survival time of the mice can be obviously prolonged, and the comparison of the difference of results among different components or combination modes is facilitated.
After the last 1 hour of administration, mice were placed into 500mL ground vials (1 each) containing 20g of soda lime, the mouths were sealed, the survival time of the mice was recorded, and the group-to-group comparisons were made.
3. Analysis method
Single factor analysis of variance is adopted for comparison among survival time groups; the survival curves for each dosing group were tested against the control group using Log-rank (Mantel-Cox).
4. Results
4.1 Atmospheric pressure hypoxia tolerance experiment
As shown in fig. 8, the survival time of the experimental method is prolonged relative to the survival time of the effect verification experiment 1, the survival rate is longer in time span, and the method is favorable for distinguishing the antioxidant effect of different components. The results show that the American ginseng single prescription, the American ginseng single prescription 2, the American ginseng single prescription 3, the American ginseng single prescription 4, the American ginseng single prescription 5 and the American ginseng single prescription 6 all show that the minimum survival time and the maximum survival time are increased, and compared with the control group, the survival rate curves (P <0.01, P <0.001, P <0.01, P <0.0001, P <0.01 and P < 0.01) of the above groups are significantly different; wherein the total dosage of the formula 4 is relatively less, the effect is relatively better, the difference between the formula and the control group is larger, and the formula has extremely significant difference (P < 0.0001). The survival rate curves of the pseudo-ginseng group, the lucid ganoderma group, the donkey-hide gelatin group and the control group have no significant difference. Therefore, the formula proportioning effect provided by the invention is superior to that of a single traditional Chinese medicine or two traditional Chinese medicine proportioning formulas.
As shown in fig. 9, both of the formulation 2 and the formulation 4 exhibited prolonged survival times (P <0.01 ) compared to the control group, with no difference therebetween. And each single party or other formulations have no significant difference from the control group in terms of the mean value of the survival time.
While the invention has been described in detail in the foregoing general description and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.

Claims (8)

1. A traditional Chinese medicine composition for improving hypoxia tolerance is characterized in that: the components of the composition are 2 parts of American ginseng, 6 parts of pseudo-ginseng, 4 parts of lucid ganoderma and 12 parts of donkey-hide gelatin in parts by weight.
2. The preparation method of the traditional Chinese medicine composition as claimed in claim 1, comprising the following steps:
s1, respectively pulverizing the American ginseng, the pseudo-ginseng and the donkey-hide gelatin, and sieving to obtain American ginseng fine powder, pseudo-ginseng fine powder and donkey-hide gelatin fine powder;
s2, sieving, drying and breaking walls of the ganoderma lucidum spore powder to obtain ganoderma lucidum fine powder;
S3, mixing the American ginseng fine powder, the pseudo-ginseng fine powder, the donkey-hide gelatin fine powder and the lucid ganoderma fine powder according to a proportion.
3. The preparation method according to claim 2, characterized in that: in the step S1, the mesh number of the sieve is 80-150 mesh.
4. A method of preparation according to claim 2 or 3, characterized in that: in the step S2, the wall breaking rate of the ganoderma lucidum fine powder is more than or equal to 95%, and the fineness is more than 300 meshes.
5. A Chinese medicinal preparation for improving anoxia tolerance comprises the Chinese medicinal composition of claim 1 as active ingredient.
6. The traditional Chinese medicine preparation according to claim 5, wherein: the traditional Chinese medicine preparation is in the form of suspension, capsule, powder, pill, tablet or paste.
7. The traditional Chinese medicine preparation according to claim 5, wherein: the traditional Chinese medicine preparation is in the form of granule.
8. Use of the traditional Chinese medicine composition of claim 1 or the traditional Chinese medicine preparation of any one of claims 5-7 in the preparation of drugs for resisting anoxia, resisting fatigue and enhancing immune function.
CN202311054722.0A 2023-08-21 2023-08-21 Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof Active CN117281846B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311054722.0A CN117281846B (en) 2023-08-21 2023-08-21 Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311054722.0A CN117281846B (en) 2023-08-21 2023-08-21 Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN117281846A CN117281846A (en) 2023-12-26
CN117281846B true CN117281846B (en) 2024-05-17

Family

ID=89239890

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311054722.0A Active CN117281846B (en) 2023-08-21 2023-08-21 Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN117281846B (en)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
三七洋参胶囊的主要药效学研究;刘维俊，刘敏，黄光才;中药药理与临床;-;19950628;第-卷(第03期);参见40页左栏第1段，摘要 *
灵芝片抗疲劳作用实验研究;孙素兰;《食品与药品》;20060831;第8卷(第06A期);44-46 *
范青生主编.《保健食品配方原理与依据》.中国医药科技出版社,2007,(第1版),105页. *
阿胶的药理作用;李宗铎等;《河南中医》;19890630;第1989年卷(第6期);27-29 *

Also Published As

Publication number Publication date
CN117281846A (en) 2023-12-26

Similar Documents

Publication Publication Date Title
RU2573990C2 (en) Preparation, containing amino acids and plants, and its activity in alcohol detoxication
CN106492048A (en) A kind of rush sleep preparation and preparation method thereof
EP3263114A1 (en) Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome
CN117281846B (en) Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof
CN105920198B (en) Cell wall-broken micropowder with blood replenishing effect and preparation method thereof
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
CN101647816A (en) Bionic enzymatic hydrolysate for animal skins and application thereof
CN115886252A (en) Food composition for promoting sleep and regulating depression mood and preparation method thereof
CN105250989A (en) Donkey-hide glue small peptide composition for resisting fatigue
CN110269897B (en) Composition for resisting fatigue and improving sleep and application thereof
CN111632074A (en) A Chinese and western medicinal composition for treating insomnia and preparation method thereof
CN113633657A (en) Pharmaceutical composition for improving anti-fatigue, anti-hypoxia, heat-resistant and cold-resistant abilities of organism and application thereof
CN1294990C (en) Composition of nanometer SOD and ginseng or its extract and its preparation method
CN108743809B (en) Throat clearing composition and preparation method and application thereof
CN105616581A (en) Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof
CN104435003A (en) Cordyceps militaris health product preparation and preparation method thereof
CN106387915B (en) Qi and coffee vigor-benefiting effervescent tablet and preparation process and application thereof
KR20010009653A (en) Composition for treating sexual dysfunction
CN1242766C (en) Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof
KR20040097813A (en) Composition containing Diet Neurotrophic Factor having anti-fatness functions
CN100339133C (en) Composition of nanometer SOD and astragalus root or its extract and its preparation method
CN113101344B (en) Traditional Chinese medicine enzyme and preparation method thereof
CN111544570B (en) Antiviral preparation added with antibacterial peptide and preparation method thereof
CN102225082A (en) Medicament for preventing and treating diabetes and complications thereof and preparation method thereof
CN107007752B (en) Traditional Chinese medicine composition for improving anoxia tolerance

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant